Anti-Inflammatory Effects of the Mediterranean Diet in the Early and Late Stages of Atheroma Plaque Development by Casas, Rosa et al.
Clinical Study
Anti-Inflammatory Effects of the Mediterranean Diet in the
Early and Late Stages of Atheroma Plaque Development
Rosa Casas,1,2 Mireia Urpi-Sardà,3 Emilio Sacanella,1,2 Sara Arranz,1,2 Dolores Corella,2,4
Olga Castañer,2,5 Rosa-María Lamuela-Raventós,2,3 Jordi Salas-Salvadó,2,6 José Lapetra,2,7
Maria P. Portillo,2,8 and Ramón Estruch1,2
1Department of Internal Medicine, Hospital Clinic, Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of
Barcelona, Villarroel 170, 08036 Barcelona, Spain
2Ciber Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
3Department of Nutrition and Food Science, School of Pharmacy, University of Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain
4Department of Epidemiology and Department of Biochemistry and Molecular Biology, School of Medicine, Valencia University,
Valencia, Spain
5Cardiovascular Risk and Nutrition and REGICOR Research Group, Hospital del Mar Medical Research Institute (IMIM),
Barcelona, Spain
6Human Nutrition Unit, Hospital Universitari de Sant Joan de Reus, IISPV, Universitat Rovira i Virgili, Reus, Spain
7Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, Sevilla, Spain
8Nutrition and Obesity Group, Department of Nutrition and Food Sciences, Lucio Lascaray Research Center, University of Basque
Country (UPV/EHU), Vitoria-Gasteiz, Spain
Correspondence should be addressed to Emilio Sacanella; esacane@clinic.ub.es
Received 20 January 2017; Accepted 14 March 2017; Published 18 April 2017
Academic Editor: Mauro M. Teixeira
Copyright © 2017 Rosa Casas et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Objective. To evaluate the long-term effects of a Mediterranean diet (MeDiet) intervention on the plasma concentrations of
inflammatory and plaque stability-related molecules in elderly people at high risk for cardiovascular disease. Design and Setting.
66 participants from primary care centers affiliated with the Hospital Clinic of Barcelona were randomized into 3 groups:
MeDiet plus extra virgin olive oil (EVOO) or nuts and a low-fat diet (LFD). At baseline and at 3 and 5 years, we
evaluated the changes in the plasma concentrations of 24 inflammatory biomarkers related to the different stages of the
atherosclerotic process by Luminex®. Results. At 3 and 5 years, both MeDiet groups showed a significant reduction of
IL-6, IL-8, MCP-1, and MIP-1β (P < 0 05; all) compared to LFD. IL-1β, IL-5, IL-7, IL-12p70, IL-18, TNF-α, IFN-γ,
GCSF, GMCSF, and ENA78 (P < 0 05; all) only decreased in the MeDiet+EVOO group and E-selectin and sVCAM-1
(P < 0 05; both) in the MeDiet+nuts group. Conclusions. Long-term adherence to MeDiet decreases the plasma
concentrations of inflammatory biomarkers related to different steps of atheroma plaque development in elderly persons at high
cardiovascular risk.
1. Introduction
Atherosclerosis is a low-grade chronic inflammatory disor-
der of the vessel wall that involves the accumulation of lipids,
especially low-density lipoproteins (LDL), in the intima.
Oxidation of LDL particles (oxLDL) leads to macrophage
activation and recruitment of monocytes, neutrophils, T-,
and B-lymphocytes [1] in the vascular wall which induces
the formation of atheroma plaque [2]. The first step of the
process is the recruitment ofmonocytes including endothelial
adhesion molecules, such as P- and E-selectins (rolling pro-
cess), and subsequently, vascular cell adhesion molecule-1
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(VCAM-1) and intercellular adhesion molecule-1 (ICAM-1)
(migration process) [3–5]. Migration of monocytes and other
immune cells is further aided by endothelial-expressed
chemokines [monocyte chemotactic protein-1 (MCP-1),
regulated on activation, normal T cell expressed and secreted
(RANTES), macrophage inflammatory protein-1β (MIP-
1β), epithelial-derived neutrophil-activating peptide 78
(ENA78), interferon-inducible T cell alpha chemoattractant
(ITAC), and interferon-inducible protein- (IP-) 10] and cyto-
kines [interleukin-6 (IL-6), IL-8, IL-12p70, IL-10, IL-18,
tumor necrosis factor-α (TNF-α), interferon-γ-inducing
factor (IFN-γ), etc.] [3–5]. After recruitment, monocytes in
the intima differentiate into macrophages, mediated by
macrophage colony-stimulating factor (M-CSF) [4–6], and
thereafter release a variety of proinflammatory cytokines
such as the soluble CD40 ligand, IL-1, IL-6, IL-8, IL-18,
IFN-γ, and TNF-α [3–5]. The growth process of atheroma
plaque leads to the formation of a fibrous cap, which contains
a large number of cytokines and chemokines; some of these,
such as IL-10 or IL-13, have a stability function [7] while
others, such as IP-10, IL-18, and IFN-γ, play a role in instabil-
ity [8]. Increases in some of these inflammatory biomarkers
have been associated with an increased risk of cardiovascular
events in patients with coronary artery disease, and thus a
large number of new inflammatory biomarkers are currently
being studied as possible mediators of inflammation [9].
The Mediterranean diet (MeDiet) is characterized by a
high intake of extra virgin olive oil (EVOO), nuts, legumes,
vegetables, fruit, fish, and whole grain products. The main
nutrients of this dietary pattern are fiber, monounsaturated
fatty acids (MUFA), n-3 polyunsaturated fatty acid (n-3
PUFA), vitamin C, vitamin E, and carotenoids, and all of
which are associated with lower inflammation against satu-
rated fatty acids (SFA) or trans fatty acids (TFA) and high-
glucose and high-fat meals which may induce postprandial
inflammation and, hence, are considered as proinflammatory
factors [10]. Thus, high MUFA and n-3 PUFA intakes have
been shown to exert anti-inflammatory effects. The Nurses’
Health Study (80,082 healthy women between 34 and 59
years of age) showed a significant association between high
intake of trans or saturated fats and an increased incidence
of CVD, whereas high n-3 PUFA and MUFA intakes were
associated with a decreased risk [11]. Thus, the effects of
several dietary patterns such as the MeDiet, SFA or MUFA,
or n-3 PUFA diets on biomarkers related to inflammation
have been studied, and it has been concluded that the MeDiet
exerts its anti-inflammatory and immunomodulating effect
through downregulation of the expression of leukocyte
adhesion molecules [12, 13], decreasing proinflammatory
interleukins (IL-1, IL-6, IL-7, IL-8, and IL-18), TNF-α and
its receptors, CRP, chemoattractant molecules (MCP-1),
and soluble endothelial adhesion molecules (sVCAM-1,
sICAM-1, sE-, and sP-selectins) [10–15].
However, in most of these studies, the follow-up was
short, with 3 to12 weeks of intervention [16]. In addition,
to date, few intervention studies have thoroughly explored
the effects of diet on inflammatory biomarkers in elderly
people at high cardiovascular risk. Thus, in the current study,
we evaluated the long-term effects of a MeDiet intervention
on most biomarkers participating in the early and late steps
of atheroma plaque development in a cohort of elderly
subjects enrolled in the PREDIMED study.
2. Methods
2.1. Design Overview. The PREDIMED (Prevención con
DietaMediterránea) study is a 5-year, parallel-group, single-
blind, multicenter, randomized, controlled feeding trial con-
ducted in Spain which aimed to assess the effects of the
MeDiet on the primary prevention of cardiovascular diseases
(CVD) (http://www.predimed.es) [17, 18]. The design, meth-
odology, and eligibility criteria for the PREDIMED study
have been described previously [17, 18].
2.2. Setting and Participants. Recruitment took place between
October 2003 and January 2009, and the 7447 participants
were randomly assigned to one of the three interventions: a
MeDiet supplemented with extra virgin olive oil (MeDiet+
EVOO), a MeDiet supplemented with nuts (MeDiet+nuts),
or a control low-fat diet (LFD). Randomization was per-
formed centrally by means of a computer-generated random-
number sequence.
The participants included were men (55 to 80 years of
age) and women (60 to 80 years of age) who were free of
CVD at the beginning of the study but had high cardiovascu-
lar risk because of the presence of either type 2 diabetes
mellitus or at least three of the following major risk factors:
current smoking, hypertension, high levels of LDL cho-
lesterol, low levels of high-density lipoprotein cholesterol,
overweight/obesity, or a family history of premature coronary
heart disease (CHD). Further details of the inclusion and
exclusion criteria have been published previously [17, 18].
Eligible participants were selected in primary care centers
affiliated with the Hospital Clinic of Barcelona, and all the
participants provided written informed consent.
In the current study, we screened 80 consecutive poten-
tial participants. Four did not fulfill the inclusion criteria,
six declined to participate, and the diet could not be changed
in one. After 5 years, 4 participants voluntarily left the study
(1 from the MeDiet+EVOO group, 1 from the MeDiet+nuts
group, and 2 from the control group). Thus, 66 were finally
included in this substudy.
2.3. Diets and Physical Activity. All the participants were ran-
domly assigned to one of the three intervention groups: a
MeDiet+EVOO, MeDiet+nuts (walnuts, almonds, and hazel-
nuts), or a LFDor control diet, as described elsewhere [17, 18].
The randomized participants had an annual face-to-face
interview with the dietitian. Group sessions took place every
3 months to provide the participants with descriptions of
seasonal foods, shopping lists, weekly meal plans, and cook-
ing recipes. These sessions were specific for each intervention
group and included no more than 20 participants per group.
In the individual sessions, a 14-item dietary screening ques-
tionnaire was used to assess adherence to the MeDiets, and
a 9-item dietary screening questionnaire was used to check
adherence to the control LFD [17, 18]. In addition, the indi-
vidual motivational interview included a 137-item validated
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food frequency questionnaire (FFQ), the Minnesota leisure-
time physical activity questionnaire and individualized
recommendations for changes to be introduced in the partic-
ipant’s diet in order to achieve a personalized goal, and lastly,
a 47-item questionnaire about education, lifestyle, history of
illnesses, and medication use was carried out. Participants
allocated to the LFD were advised to reduce all types of fat
and received written recommendations according to the
American Heart Association guidelines. For the 2 MeDiets,
the focus was shifted to increase the intake of vegetables
(≥2 servings/d), fresh fruit (≥3 servings/d), legumes, nuts,
fish or seafood (≥3 servings/wk), and the use of olive oil
for cooking and dressings. The detailed protocol including
study design, rationale, and organization has been published
elsewhere [17, 18].
Participants in the two intervention groups were given
supplementary foods at no cost: either EVOO (1 liter/week for
theparticipant and their families) ormixednuts (30 g/day: 15 g
walnuts, 7.5 g hazelnuts, and 7.5 g almonds) according to the
group to which they were randomized.
Energy restriction was not specifically advised nor was
physical activity promoted in any of the three groups.
2.4. Ethics Statement. All participants provided signed
informed consent. The Institutional Review Board of the
Hospital Clinic (Barcelona, Spain), accredited by the US
Department of Health and Human Services (DHHS) update
for Federalwide Assurance for the Protection of Human
Subjects for International (Non-US) Institutions number
00000738, approved the study protocol on July 16, 2002.
The trial was registered (ISRCTN35739639).
2.5. Laboratory Measurements. The main outcome measure-
ments were changes in 24 plasma inflammatory biomarkers
and all of which are related to the different stages of the
atherosclerotic process at baseline and at 3 and 5 years of
dietary intervention; IL-1β, IL-4, IL-5, IL-6, IL-7, IL-8, IL-
10, IL-12p70, IL-13, IL-18, TNF-α, MCP-1, RANTES/CCL5,
MIP-1β/CCL4, IP-10/CXCL10, IFN-γ, granulocyte colony-
stimulating factor (GCSF), and granulocyte-macrophage
colony-stimulating factor (GMCSF) were determined using
the Bio-Plex Pro™ cytokine, adhesion molecule, and chemo-
kine assays (Bio-Rad Laboratories Inc., Hercules, CA, USA)
based on magnetic bead-based multiplex assays designed to
measure multiple cytokines, adhesion molecules, and chemo-
kines in plasma matrices.
On the other hand, ENA78/CXCL5, ITAC/CXCL11s,
soluble VCAM-1 (sVCAM), soluble ICAM-1 (sICAM-1),
and E- and P-selectins were determined using the Versa-
MAP™ human custom multi-analyte profiling development
system (R&D Systems, Abingdon, UK) which is also based
on multiplex assays designed to measure analytes in plasma
matrices. Data from the reactions were acquired using the
Luminex 100™ System (Luminex, Austin, TX), a high-speed
digital processor that efficiently manages the data output
which is further analyzed and presented as fluorescence
intensity and target concentration. Thereafter, the data were
processed and analyzed with the Bio-Plex Manager 6.1™
(Bio-Rad, Hercules, CA). Plasma samples were diluted 1 : 3
with the diluents provided for each assay. Concentrations
were obtained by standard calibration curves. We performed
all the analyses in duplicate.
2.6. Statistical Analyses. Statistical analyses were performed
using the SPSS, version 22.0 (SPSS Inc., Chicago, IL). Vari-
ables are presented as mean and standard deviation (SD) or
standard error of the mean (SEM) as appropriate. Categorical
variables are expressed as percentages. Plasma inflammatory
biomarkers (ITAC) had a skewed distribution (Kolmogorov
and Levene tests) and were thus transformed to their natural
logarithm for analysis. Changes in food and nutrient intake
as well as changes in inflammatory biomarkers were mea-
sured using repeated measures ANOVA to test the effects
of the interaction of 2 factors: time as a within-participants
factor with 2 levels (first, at baseline and at 3 years, second,
at baseline and at 5 years, and third, at 3 and 5 years) and
the 3 intervention groups, adjusting for potential confound-
ing variables such as age, sex, weight, smoking status, blood
pressure systolic and diastolic, oral hypoglycemic agents,
and statins and triglyceride levels. To test the effects of indi-
vidual factors, we calculated the differences between 3 years
and baseline and 5 years and baseline values for the adhesion
molecules and inflammatory molecules and then applied an
ANOVA test with the intervention group as fixed factors.
Significant interactions were assessed by simple effect analy-
sis. All the multiple contrasts were adjusted by a Bonferroni
post hoc test. Within- and between-group differences were
expressed as estimated means and 95% confidence interval
(95% CI). Significance was set at P < 0 05.
3. Results
3.1. Study Population. Of the 69 participants included, equal
numbers (n=23) were randomized into each of the three
intervention groups. Figure 1 shows the retention rates
(≥95% for all) for the 3- and 5-year follow-ups. As shown
in Table 1, all the participants (22 per group) selected had
similar characteristics to those of the whole group (demo-
graphic characteristics, medication taken, and adiposity and
CVD risk factors). We did not observe significant changes
in medication use during the 5 years of intervention. On
average, the participants were 67 years old and nearly half
were men. Most participants (≥90%) were overweight or
obese, ≥50% had hypertension and dyslipidemia, and ≥60
had diabetes.
3.2. Food, Energy Balance, and Dietary Adherence. As shown
in Supplemental Table 1 available online at https://doi.org/10
.1155/2017/3674390, we observed a significant increase in
EVOO consumption (P = 0 001) and a decrease in refined
olive oil consumption (P ≤ 0 003) in the MeDiet+EVOO at
3 and 5 years. Similarly, nut consumption increased in the
MeDiet+nuts group (P ≤ 0 01) at 3 and 5 years of interven-
tion, contrary to the other two groups. At 3 and 5 years of
intervention, both MeDiets showed an increase in the con-
sumption of vegetables (P ≤ 0 02), legumes (P ≤ 0 04), fruit
(P < 0 05), and fish (P ≤ 0 02) and a reduction in the intake
of cereals (P ≤ 0 02) and meat or meat products (P < 0 05).
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Furthermore, the consumption of cereals (P ≤ 0 04) andmeat
or meat products (P ≤ 0 007) decreased in the LFD group
at 3 and 5 years of intervention as did the intake of vege-
tables at 5 years of intervention. Adherence to the MeDiet
(P < 0 001) increased at 3 and 5 years of intervention in
both MeDiet groups.
Adherence to supplemental foods was good in the two
MeDiets. MUFA levels increased from baseline in the MeD-
iet+EVOO group (P < 0 001), and α-linolenic acid levels
increased in the MeDiet+nuts group (P ≤ 0 009) compared
to the other diets at 3 and 5 years of follow-up. A reduction
in energy (P ≤ 0 03; both), carbohydrate (P ≤ 0 01; both),
and cholesterol (P ≤ 0 03; both) intake was observed in the
3 groups at 3 and 5 years (Supplemental Table 2). Partici-
pants in the twoMeDiet groups increased their intake of total
fiber (P ≤ 0 02; both), total fat (P ≤ 0 04; both), and marine
ω-3 (P ≤ 0 007; both) and reduced their intake of saturated
fat (P ≤ 0 02; both). The three groups showed a reduced con-
sumption of protein (P ≤ 0 04; all) after 5 years, although the
control group also showed a reduction (P = 0 02) at 3 years of
intervention. At both assessment points, polyunsaturated
fatty acid (PUFA) intake significantly increased in the partic-
ipants in the MeDiet+nuts group (P < 0 001).
3.3. Plasma Levels of Colony-Stimulating Factors and Soluble
Endothelial Molecules. As shown in Table 2, GCSF and
GMCSF (P ≤ 0 04, both) decreased in the MeDiet+EVOO
group at 3 and 5 years of dietary intervention. The LFD
group showed increased CGSF levels at 3 and 5 years
(P ≤ 0 03). In addition, the MeDiet+nuts group showed
lower serum E-selectin levels (P ≤ 0 02), and the LFD group
showed an increase in sVCAM-1 serum levels (P ≤ 0 03) in
both evaluations. On the other hand, the LFD group showed
higher levels of P-selectin (P = 0 03) at 5 years of dietary
Assessed for eligibility (n = 80)
Excluded (n = 11)
Assigned to MeDiet enriched
with extra virgin olive oil,
MeDiet+EVOO (n = 23)
Assigned to control low-fat
diet (n = 23)
Randomized (n = 69)
Assigned to MeDiet
enriched with mixed nuts,
MeDiet+nuts (n = 23)
3-year follow-up (n = 23)
(0% of lost to follow-up)
3-year follow-up (n = 23)
(0% of lost to follow-up)
3-year follow-up (n = 23)
(0% of lost to follow-up)
5-year follow-up (n = 22)
(4.3% of lost to follow-up)
5-year follow-up (n = 22)
(4.3% of lost to follow-up)
5-year follow-up (n = 22)







(i) Not meeting inclusion criteria (n = 4)
(ii) Declined to participate ( n = 6)
(iii) Not able to change diet (n = 1)
Figure 1: Flowchart of the study participants. The diagram includes detailed information on the participants excluded. EVOO: extra virgin
olive oil; MeDiet: Mediterranean diet.
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intervention. No changes were observed in sICAM-1 concen-
trations at 3 and 5 years of intervention.
Comparisons among the 3 intervention groups showed a
significant increase ≥ 40% in CGSF at 3 and 5 years in the
LFD group compared to both MeDiet groups, while MeDiet
+nuts participants reduced E-selectin concentrations by
14% compared to the LFD group after 5 years of intervention
(P < 0 05; all).
3.4. Plasma Levels of Inflammatory Chemokines. Serum levels
of MCP-1 (P ≤ 0 03) and MIP-1β (P < 0 05) decreased in
both MeDiets at 3 and 5 years of intervention (Table 3).
ENA78 and RANTES (P ≤ 0 02; both) decreased in the
MeDiet+EVOO group at 3 and 5 years of follow-up. RANTES
also decreased in theMeDiet+nuts group (P < 0 05) at 5 years
of intervention. On the other hand, the LFD group showed an
increase in RANTES (P ≤ 0 04), ENA78 and ITAC (P ≤ 0 03),
and IP-10 (P ≤ 0 003) levels at 3 and 5 years.
Comparisons among groups showed significant reduc-
tions of 20% in MCP-1 and 15% in MIP-1β levels in both
MeDiet groups at 3 and 5 years of intervention compared
to the LFD group. On the other hand, RANTES and
ENA78 increased from 25 to 50% in the LFD group
compared to both MeDiet groups at 3 and 5 years of nutri-
tional intervention.
3.5. Plasma Levels of Inflammatory Cytokines. After 3 and
5 years of intervention (Table 4), bothMeDiet groups showed
lower serum concentrations of IL-6 and IL-8 (P < 0 05; both)
compared to baseline. Furthermore, the MeDiet+EVOO
group also had lower levels of IL-1β, IL-5, and TNF-α
(P ≤ 0 03, all), IL-7 (P ≤ 0 04), IL-12p70, and IFN-γ (P < 0 05;
both) in both assessments. At 5 years, the MeDiet+nuts
group showed an improvement in the plasma levels of
IL-1β, IL-5, and TNF-α (P < 0 05; all), IL-7 (P ≤ 0 02),
IL-12p70 (P ≤ 0 04), and IFN-γ (P ≤ 0 03). In addition,
the LFD group showed an increase in the plasma concentra-
tions of IL-7 and IL-8 (P < 0 05; both) at 5 years while no
changes were observed in IL-4 at 3 or 5 years intervention.
On comparing the 3 intervention groups, we found sig-
nificant reductions of 30–50% for IL-5, IL-12p70, TNF-α,
and IFN-γ, and of 35–40% for IL-6 and IL-8 in both MeDiet
groups after 5 years of intervention compared to the LFD
group. Moreover, the MeDiet+EVOO group showed a sig-
nificant reduction of greater than 30% in IL-1β after 3 and
5 years of intervention, while the LFD cohort showed an
Table 1: Baseline characteristics of the participants at high risk for cardiovascular disease included in the study and classified according to the
dietary intervention administered.
MeDiet+EVOO MeDiet+nuts Low-fat diet P2
Age, years 67.8± 4.81 66.0± 5.8 66.0± 7.1 0.50
Men, n (%) 10 (46)1 12 (55) 9 (41) 0.66
Family history of CHD, n (%) 5 (23) 4 (18) 7 (32) 0.56
Smoking status, n (%) 0.33
Never smoked 17 (72) 12 (55) 14 (64)
Former smoker 4 (18) 6 (27) 3 (14)
Current smoker 1 (4) 4 (18) 5 (22)
BMI, kg/m2 29.7± 3.7 30.4± 3.2 28.5± 3.6 0.20
BMI≥ 25 kg/m2, n (%) 22 (100) 21 (96) 20 (90) 0.29
Waist circumference, cm 101± 10 106± 7 102± 7 0.11
Type 2 diabetes, n (%) 16 (73) 15 (68) 13 (59) 0.62
Hypertension, n (%) 18 (82) 18 (82) 14 (64) 0.27
Dyslipidemia, n (%) 10 (46) 13 (64) 13 (64) 0.58
Medications, n (%)
ACE inhibitors 2 (9) 3 (14) 5 (23) 0.44
Diuretics 4 (18) 5 (23) 4 (18) 0.91
Other antihypertensive agents 1 (5) 2 (9) 1 (5) 0.77
Statins 4 (18) 5 (23) 4 (18) 0.91
Other lipid-lowering agents 1 (5) 0 (0) 2 (9) 0.35
Insulin 1 (5) 3 (14) 3 (14) 0.53
Oral hypoglycemic drugs 9 (41) 8 (36) 9 (41) 0.94
Aspirin or antiplatelet drugs 1 (5) 6 (27) 3 (14) 0.11
NSAIDS 3 (14) 6 (27) 3 (14) 0.40
1Values are means ± SDs, n = 22 unless expressed otherwise. 2From Pearson’s chi-square test for categorical variables and one-factor ANOVA for continuous
variables. ACE: angiotensin-converting enzyme; BMI: body mass index; CHD: coronary heart disease; EVOO: extra virgin olive oil; MeDiet+EVOO:















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































increase of 39% after 5 years of intervention compared to
both MeDiet groups (P < 0 05; all).
3.6. Biomarkers Related to Plaque Stability. The MeDiet+
EVOO group showed lower levels of the instability marker
IL-18 (P ≤ 0 04) at 3 and 5 years after beginning the inter-
vention and higher levels of the stability markers IL-13
(P ≤ 0 04) and IL-10 (P ≤ 0 03) after 5 years (Table 5).
Compared to the LFD group, IL-18 levels in the MeDiet+
EVOO group were reduced more than 20% after 3 and
5 years of intervention (P = 0 002).
4. Discussion
The results of the present study in elderly persons at high
cardiovascular risk suggest that long-term adherence to a
MeDiet could delay atheroma plaque development by reduc-
ing rolling, adhesion, and migration processes of circulatory
mononuclear cells into the arterial wall. In addition, our data
suggest that the MeDiet also decreases plaque vulnerability
by lowering instability factors (IL-18) and increasing stability
factors (IL-10 and IL-13).
Although the atherogenic process begins at very early
ages (second and third decades of life), clinical events (e.g.,
stroke, acute myocardial infarction) develop after the age of
50 [19]. It is already known that ongoing inflammation is also
crucial in the development of instability and rupture of ather-
omatous plaque and the subsequent appearance of ischemic
events [20]. In this regard, severalmechanisms have been pro-
posed to explain how theMeDiet exerts its anti-inflammatory
properties. Some evidence show that theMeDiet or some of its
main foods could modulate the expression of genes related to
plaque stability such as MMP-9 [21], or they may diminish
the plasma levels of IL-18 [12], sSelectin-1, sICAM-1, and
sVCAM-1 or other biomarkers of inflammation (TNFR-60,
TNFR-80, IL-6, and CRP) [12–15, 17]. Thus, consumption
of a tomato-based drink for 26 days lowered TNF-α secretion
by 34% [22], while the consumption of EVOO and vegetables
was associated with a reduction of circulating TNFR-60 [14].
In the Multi-Ethnic Study of Atherosclerosis (MESA) trial, a
“vegetables and fish pattern” was inversely related to CRP
and sSelectin [23] concentrations, and in a second interven-
tional study, supplements of DHA, CRP, IL-6, GMCSF, and
GCSF concentrations decreased after 90 days of intervention
[24]. Several studies with olive oil, which is rich in antioxi-
dant polyphenols, and MUFA have described reduced IL-6,
sVCAM-1, and sICAM-1 levels [17, 25] in addition to other
biomarkers such as CRP, IL-7, or IL-18 [26]. Finally, the
intake of whole grains [23], fiber [27], or wine [28] has also
been associated with an improvement in inflammatory pro-
cesses reducing biomarkers such as hs-CRP, IL-6, IL-1α,
TNFα-R2, MCP-1, sICAM-1, or sVCAM-1.
According toour results, long-termadherence to aMeDiet
pattern seems to delay the progression of atheroma plaque
and seems to agree with data published in a previous
PREDIMED substudy, in which participants with a high
carotid atherosclerotic burden allocated to the MeDiet sup-
plemented with either EVOO or nuts showed reduction in
the mean common carotid artery intima-media thickness
(CCA-IMT) at 1 year compared with participants assigned
to the control diet [29]. This healthy effect is evident in early
as well as late stages of atherosclerosis since it affects bio-
markers with a role in both phases of this process. Thus,
monocyte/macrophage accumulation at the lesion site is a
key factor in atherosclerotic disease and involves several steps
including monocyte recruitment by increased levels of adhe-
sion molecules (sVCAM, sICAM, E-, and P-selectins) and
chemotactic factors (MCP-1, MIP-1β, IP-10, and RANTES),
the induction of activation, differentiation, and prolifera-
tion processes, and immobilization of macrophages in the
inflamed plaque [30]. M-CSF, which is present in the cir-
culation, predominantly produces M2-type macrophages
with increased phagocytic activity and characterized by
the expression of interleukin IL-10 [30]. On the other hand,
GMCSF produces M1-polarized cells with antigen presenta-
tion capacities, which express TNF-α and other proinflam-
matory cytokines such as IL-1β, IL-6, IL-8, and IL-12 [30].
The results of other studies [12–15, 17] agree with these
results, and accordingly, both MeDiets showed an improve-
ment in the chemokines (MCP-1, MIP-1β, RANTES, and
ENA78), colony-stimulating (GCSF and GMCSF), cytokines
(IL-1β, 5, 6, 7, 8, 12, TNF-α, and IFN-γ), and vulnerability
plaque marker (IL-10, 13, and 18) levels.
These findings may be explained by the synergy of
specific foods (fruits, vegetables, olive oil, and fish) and/or
their specific nutrients such as flavonoids, α-tocopherol,
ascorbic acid, β-carotene, and ω-3 PUFA or also by the
Mediterranean pattern itself.
The suggestion that a MeDiet could modulate the ex-
pression of biomarkers implicated in the first (endothelial
adhesion molecules, cytokines, chemokines, etc.) as well as
the late stages (molecules related with stability of the plaque)
of atheroma plaque development indicates that the MeDiet
could be a good preventive tool not only in the primary but
also in the secondary prevention of CVD.
The strengths of our study are its design (randomized
intervention trial) excellent completion rates, close monitor-
ing of the participants, and the myriad of inflammatory
biomarkers studied. Additional strengths are the length of
follow-up (5 years) and good compliance of all the partici-
pants. Nonetheless, some limitations are also acknowledged:
first, the sample size was relatively small and second, the
results cannot be generalized to the overall population
because our participants were older subjects at high risk for
CVD living in a Mediterranean country.
5. Conclusions
The present study supports the recommendation that the
MeDiet is a very useful dietary pattern in the primary pre-
vention of CVD. The results of this study show that the
MeDiet and its antioxidant compounds interfere with the
atherosclerotic inflammatory process by downregulating
proinflammatory biomarkers and upregulating biomarkers
related to atheroma stability plaque. Moreover, our results
suggest that this anti-inflammatory effect is maintained in
the long term.
10 Mediators of Inflammation
Conflicts of Interest
Ramón Estruch reports serving on the board of and receiving
lecture fees from the Research Foundation on Wine and
Nutrition (FIVIN); serving on the boards of the Beer and
Health Foundation and the European Foundation for Alco-
hol Research (ERAB); receiving lecture fees from Cerveceros
de España and Sanofi-Aventis; and receiving grant support
through his institution from Novartis. Jordi Salas-Salvadó
serves on the board of and has received grant support from
the International Nut and Dried Fruit Council; he has
received consulting fees from Danone and has received grant
support from Eroski and Nestlé. Rosa-María Lamuela-
Raventós reports serving on the board of and receiving lec-
ture fees from FIVIN, receiving lecture fees from Cerveceros
de España, and receiving lecture fees and travel support from
PepsiCo. No other potential conflict of interest relevant to
this article was reported.
Authors’ Contributions
The contributions of the different authors were as follows:
Ramón Estruch, Rosa Casas, Mireia Urpi-Sardà, and Emilio
Sacanella for the study conception and design; Rosa Casas
and Olga Castañer for the laboratory and clinical data; Rosa
Casas, Emilio Sacanella, Mireia Urpi-Sardà, and Ramón
Estruch for the analysis and interpretation of the data; Rosa
Casas, Emilio Sacanella, Rosa-María Lamuela-Raventós, and
Ramón Estruch for the draft of the article; and Rosa Casas,
Emilio Sacanella, Mireia Urpi-Sardà, Dolores Corella, Olga
Castañer, Rosa-María Lamuela-Raven, Jordi Salas-Salvadó,
Maria P. Portillo, José Lapetra, and Ramón Estruch for the
critical revision and final approval. Rosa Casas, Mireia Urpi-
Sardà, Emilio Sacanella, and Ramón Estruch wrote the paper.
Ramón Estruch had primary responsibility for the final
content. All the authors have read and approved the final
manuscript. Rosa Casas and Mireia Urpi-Sardà contributed
equally to this work.
Acknowledgments
The authors are grateful to the Fundación Patrimonio
Comunal Olivarero, the California Walnut Commission
(Sacramento, CA), and Borges SA andMorella Nuts SA, both
from Reus, Spain, for generously donating the olive oil,
walnuts, almonds, and hazelnuts, respectively, used in the
study. CIBEROBN is an initiative of the Instituto de Salud
Carlos III, Spain. This work has been partially supported by
PI13/02184 from the Instituto de Salud Carlos III, Spain.
Mireia Urpi-Sardà was supported by the “Ramon y Cajal”
program of MINECO and Fondo Social Europeo.
References
[1] G. K. Hansson and A. Hermansson, “The immune system
in atherosclerosis,” Nature Immunology, vol. 12, no. 3,
pp. 204–212, 2011.
[2] A. M. Lundberg and G. K. Hansson, “Innate immune
signals in atherosclerosis,” Clinical Immunology, vol. 134,
no. 1, pp. 5–24, 2010.
[3] K. J. Moore, F. J. Sheedy, and E. A. Fisher, “Macrophages in
atherosclerosis: a dynamic balance,”Nature Reviews Immunol-
ogy, vol. 13, no. 10, pp. 709–721, 2013.
[4] R. Kleemann, S. Zadelaar, and T. Kooistra, “Cytokines and
atherosclerosis: a comprehensive review of studies in mice,”
Cardiovascular Research, vol. 79, no. 3, pp. 360–376, 2008.
[5] J. E. McLaren, D. R. Michael, T. G. Ashlin, and D. P. Ramji,
“Cytokines, macrophage lipid metabolism and foam cells:
implications for cardiovascular disease therapy,” Progress in
Lipid Research, vol. 50, no. 4, pp. 331–347, 2011.
[6] J. L. Johnson and A. C. Newby, “Macrophage heterogeneity in
atherosclerotic plaques,” Current Opinion in Lipidology,
vol. 20, no. 5, pp. 370–378, 2009.
[7] M. L. Buckley and D. P. Ramji, “The influence of dysfunctional
signaling and lipid homeostasis in mediating the inflammatory
responses during atherosclerosis,” Biochimica et Biophysica
Acta, vol. 1852, no. 7, pp. 1498–1510, 2015.
[8] E. P. van der Vorst, Y. Döring, and C. Weber, “Chemokines
and their receptors in atherosclerosis,” Journal of Molecular
Medicine, vol. 93, no. 9, pp. 963–971, 2015.
[9] S. B. Larsen, E. L. Grove, M. Würtz, S. Neergaard-Petersen,
A. M. Hvas, and S. D. Kristensen, “The influence of low-
grade inflammation on platelets in patients with stable
coronary artery disease,” Thrombosis and Haemostasis,
vol. 114, no. 3, pp. 519–529, 2015.
[10] P. C. Calder, N. Ahluwalia, F. Brouns et al., “Dietary factors
and low-grade inflammation in relation to overweight and
obesity,” The British Journal of Nutrition, vol. 106, Supplement
3, pp. S1–S78, 2011.
[11] F. B. Hu, M. J. Stampfer, J. E. Manson et al., “Dietary fat intake
and the risk of coronary heart disease in women,” The New
England Journal of Medicine, vol. 337, no. 21, pp. 1491–1499,
1997.
[12] R. Casas, E. Sacanella, M. Urpí-Sardà et al., “The effects of the
mediterranean diet on biomarkers of vascular wall inflam-
mation and plaque vulnerability in subjects with high risk for
cardiovascular disease. A randomized trial,” PLoS One, vol. 9,
no. 6, article e100084, 2014.
[13] M.-P. Mena, E. Sacanella, M. Vazquez-Agell et al., “Inhibi-
tion of circulating immune cell activation: a molecular
anti-inflammatory effect of the Mediterranean diet,” The
American Journal of Clinical Nutrition, vol. 89, no. 1,
pp. 248–256, 2008.
[14] M. Urpi-Sarda, R. Casas, G. Chiva-Blanch et al., “The Mediter-
ranean diet pattern and its main components are associated
with lower plasma concentrations of tumor necrosis factor
receptor 60 in patients at high risk for cardiovascular disease,”
The Journal of Nutrition, vol. 142, no. 6, pp. 1019–1025, 2012.
[15] R. Casas, E. Sacanella, M. Urpí-Sardà et al., “Long-term immu-
nomodulatory effects of a Mediterranean diet in adults at high
risk of cardiovascular disease in the PREvención con DIeta-
MEDiterránea (PREDIMED) randomized controlled trial,”
The Journal of Nutrition, vol. 146, no. 9, pp. 1684–1693, 2016.
[16] J. Barbaresko, M. Koch, M. B. Schulze, and U. Nöthlings, “Die-
tary pattern analysis and biomarkers of low-grade inflamma-
tion: a systematic literature review,” Nutrition Reviews,
vol. 71, no. 8, pp. 511–527, 2013.
[17] R. Estruch, M. A. Martinez-Gonzalez, D. Corella et al., “Effects
of a Mediterranean-style diet on cardiovascular risk factors: a
randomized trial,” Annals of Internal Medicine, vol. 4, no. 1,
pp. 1–11, 2006.
11Mediators of Inflammation
[18] R. Estruch, E. Ros, J. Salas-Salvadó et al., “Primary prevention
of cardiovascular disease with a Mediterranean diet,” The New
England Journal of Medicine, vol. 368, no. 14, pp. 1279–1290,
2013.
[19] M. A. Arce-Torres, M. E. Haro, G. Ponce y Ponce De León
et al., “Aterogenesis,” Respsvin, vol. 9, no. 4, 2008.
[20] A. V. Finn, M. Nakano, J. Narula, F. D. Kolodgie, and R.
Virmani, “Concept of vulnerable/unstable plaque,” Arterio-
sclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 7,
pp. 1282–1292, 2010.
[21] A. Camargo, J. Delgado-Lista, A. Garcia-Rios et al., “Expres-
sion of proinflammatory, proatherogenic genes is reduced by
the Mediterranean diet in elderly people,” The British Journal
of Nutrition, vol. 108, no. 3, pp. 500–508, 2012.
[22] P. Riso, F. Visioli, S. Grande et al., “Effect of a tomato-based
drink on markers of inflammation, immunomodulation, and
oxidative stress,” Journal of Agricultural and Food Chemistry,
vol. 54, no. 7, pp. 2563–2566, 2006.
[23] J. A. Nettleton, L. M. Steffen, E. J. Mayer-Davis et al., “Dietary
patterns are associated with biochemical markers of inflamma-
tion and endothelial activation in the Multi-Ethnic Study of
Atherosclerosis (MESA),” The American Journal of Clinical
Nutrition, vol. 83, no. 6, pp. 1369–1379, 2006.
[24] D. S. Kelley, D. Siegel, D. M. Fedor, Y. Adkins, and B. E.
Mackey, “DHA supplementation decreases serum C-reactive
protein and other markers of inflammation in hypertrigly-
ceridemic men,” The Journal of Nutrition, vol. 139, no. 3,
pp. 495–501, 2009.
[25] A. Medina-Remón, R. Casas, A. Tressserra-Rimbau et al.,
“Polyphenol intake from a Mediterranean diet decreases
inflammatory biomarkers related to atherosclerosis: a sub-
study of the PREDIMED trial,” British Journal of Clinical
Pharmacology, vol. 83, no. 1, pp. 114–128, 2016.
[26] K. Esposito, R. Marfella, M. Ciotola et al., “Effect of a
mediterranean-style diet on endothelial dysfunction and
markers of vascular inflammation in the metabolic syndrome:
a randomized trial,” Jama, vol. 292, no. 12, pp. 1440–1446,
2004.
[27] Y. Ma, J. R. Hébert, W. Li et al., “Association between dietary
fiber and markers of systemic inflammation in the Women’s
Health Initiative Observational Study,” Nutrition, vol. 24,
no. 10, pp. 941–949, 2008.
[28] G. Chiva-Blanch, S. Arranz, R. M. Lamuela-Raventos, and
R. Estruch, “Effects of wine, alcohol and polyphenols on
cardiovascular disease risk factors: evidences from human
studies,” Alcohol and Alcoholism, vol. 48, no. 3, pp. 270–277,
2013.
[29] M. Murie-Fernandez, P. Irimia, E. Toledo et al., “Carotid
intima-media thickness changes with Mediterranean diet: a
randomized trial (PREDIMEDNavarra),” Atherosclerosis,
vol. 219, no. 1, pp. 158–162, 2011.
[30] H. Mangge, K. Becker, D. Fuchs, and J. M. Gostner, “Antioxi-
dants, inflammation and cardiovascular disease,” World
Journal of Cardiology, vol. 6, no. 6, pp. 462–477, 2014.
12 Mediators of Inflammation



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
